Mar 14, 2023 / 06:40PM GMT
Matt Biegler - Oppenheimer & Co. Inc. - Analyst
Hey, good afternoon, everyone. Thanks for joining the Annual Healthcare Conference. My name is Matt Biegler. I'm a covering analyst here. Pleased to be joined by one of my covered companies, which is Medicenna. We're with CEO, Fahar Merchant. Fahar, welcome.
Fahar Merchant - Medicenna Therapeutics Corp. - President & CEO
Thank you, and thank you, Matt, for inviting us to participate in your conference today.
Questions and Answers:
Matt Biegler - Oppenheimer & Co. Inc. - AnalystWe are going to be doing a fireside chat for those interested. So maybe I'll just start with the high level question. I think a lot of people think of medicine as kind of a one trick pony in the IL-2 space, with a modified IL-2 agonist, which is MDNA11. We'll obviously talk a lot about -- a lot of it I've heard about that today. But there's much more to Medicenna, I guess, that you guys have under the hood. So maybe if you can just walk us through the story and what you guys are
Trustpilot
